Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-vpsfw Total loading time: 0 Render date: 2024-07-20T00:34:10.897Z Has data issue: false hasContentIssue false

3 - CHALLENGES IN ATHEROSCLEROSIS

Published online by Cambridge University Press:  04 April 2011

By
John S. Millar
Edited by
Bruce H. Littman  and
Rajesh Krishna
John S. Millar
Affiliation:
University of Pennsylvania
Bruce H. Littman
Affiliation:
Translational Medicine Associates
Rajesh Krishna
Affiliation:
Merck Research Laboratories
Get access

Summary

Introduction

Atherosclerotic cardiovascular disease is the leading cause of death worldwide today. The number of cases of cardiovascular disease is anticipated to increase from 17.5 million to 24.2 million through the year 2030 as rates of obesity and insulin resistance and their associated dyslipidemia (elevated triglycerides and low-density lipoprotein [LDL] cholesterol and reduced high-density lipoprotein [HDL] cholesterol) continue to rise. One proven means of reducing the incidence of cardiovascular disease is through reduction of LDL cholesterol levels. Although currently accepted as a way of reducing cardiovascular disease risk, this has not always been the case. Over the past 50 years, the lipid hypothesis, which states that high LDL cholesterol and remnant lipoprotein levels cause atherosclerotic cardiovascular disease, has had its skeptics. Several competing theories have been proposed regarding the factors responsible for the development of atherosclerosis. The following section will provide a brief overview of several theories of atherosclerosis development and show where we stand today. Much of the evidence supporting the lipid hypothesis has recently been reviewed in detail.

Prevailing Hypotheses of Atherosclerosis Development

The Lipid Hypothesis

Early investigations into the structure and composition of atherosclerotic plaque revealed that plaque is enriched in lipid, including cholesterol. How and why it forms was not initially known. Anitschkow and Chalatow made the serendipitous discovery in their studies on dietary protein that feeding egg yolk and brain to rabbits resulted in atherosclerotic plaque formation. They also noted that these animals had an accumulation of lipid in the liver.

Type
Chapter
Information
Translational Medicine and Drug Discovery , pp. 62 - 88
Publisher: Cambridge University Press
Print publication year: 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

MacKay, J, & Mensah, GA. (2004). The Atlas of Heart Disease and Stroke. Geneva, Switzerland: World Health Organization.Google Scholar
(1984). The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 251, 351–364.CrossRef
Frick, MH, Elo, O, Haapa, K, Heinonen, OP, Heinsalmi, P, Helo, P, et al. (1987). Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317, 2137–2145.CrossRefGoogle ScholarPubMed
Shepherd, J, Cobbe, SM, Ford, I, Isles, CG, Lorimer, AR, MacFarlane, PW, et al. (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333, 1301–1307.CrossRefGoogle ScholarPubMed
(1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 344, 1383–1389.
Steinberg, D. (2004). Thematic review series: The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: Part I. J. Lipid Res. 45, 1583–1593.CrossRefGoogle ScholarPubMed
Steinberg, D. (2005). Thematic review series: The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: Part II: The early evidence linking hypercholesterolemia to coronary disease in humans. J. Lipid Res. 46, 179–190.CrossRefGoogle ScholarPubMed
Steinberg, D. (2005). Thematic review series: The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: Part III: Mechanistically defining the role of hyperlipidemia. J. Lipid Res. 46, 2037–2051.CrossRefGoogle ScholarPubMed
Steinberg, D. (2006). The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: Part IV: The 1984 coronary primary prevention trial ends it–almost. J. Lipid Res. 47, 1–14.CrossRefGoogle Scholar
Steinberg, D. (2006). Thematic review series: The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: Part V: The discovery of the statins and the end of the controversy. J. Lipid Res. 47, 1339–1351.CrossRefGoogle Scholar
(1983). Classics in arteriosclerosis research: On experimental cholesterin steatosis and its significance in the origin of some pathological processes by N. Anitschkow and S. Chalatow, translated by Mary Z. Pelias, 1913. Arteriosclerosis. 3, 178–182.
Keys, A, Aravanis, C, Blackburn, HW, Buchem, FS, Buzina, R, Djordjević, BD, et al. (1966). Epidemiological studies related to coronary heart disease: Characteristics of men aged 40–59 in seven countries. Acta Med. Scand. Suppl. 460, 1–392.Google ScholarPubMed
Kato, H, Tillotson, J, Nichaman, MZ, Rhoads, GG, & Hamilton, HB. (1973). Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California. Am. J. Epidemiol. 97, 372–385.CrossRefGoogle ScholarPubMed
Thompson, GR, Miller, JP, & Breslow, JL. (1985). Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. Br. Med. J. (Clin. Res. Ed.) 291, 1671–1673.CrossRefGoogle ScholarPubMed
Levy, RI. (1985). Primary prevention of coronary heart disease by lowering lipids: Results and implications. Am. Heart J. 110, 1116–1122.CrossRefGoogle ScholarPubMed
Shepherd, J. (1998). A tale of two trials: The West of Scotland Coronary Prevention Study and the Texas Coronary Atherosclerosis Prevention Study. Atherosclerosis. 139, 223–229.CrossRefGoogle ScholarPubMed
Keys, A, Aravanis, C, Blackburn, H, Buzina, R, Dontas, AS, Fidanza, F, et al. (1985). Serum cholesterol and cancer mortality in the Seven Countries Study. Am. J. Epidemiol. 121, 870–883.CrossRefGoogle ScholarPubMed
Law, MR, Thompson, SG, & Wald, NJ. (1994). Assessing possible hazards of reducing serum cholesterol. BMJ. 308, 373–379.CrossRefGoogle ScholarPubMed
Brest, AN. (1964). Treatment of coronary occlusive disease: Critical review. Dis. Chest. 45, 40–45.CrossRefGoogle ScholarPubMed
Ross, R, Glomset, J, & Harker, L. (1977). Response to injury and atherogenesis. Am. J. Pathol. 86, 675–684.Google ScholarPubMed
Ross, R. (1999). Atherosclerosis–an inflammatory disease. N. Engl. J. Med. 340, 115–126.CrossRefGoogle ScholarPubMed
Williams, KJ, & Tabas, I. (1995). The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15, 551–561.CrossRefGoogle ScholarPubMed
Wilson, PWF, D'Agostino, RB, Levy, D, Belanger, AM, Silbershatz, H, & Kannel, WB. (1998). Prediction of coronary heart disease using risk factor categories. Circulation. 97, 1837–1847.CrossRefGoogle ScholarPubMed
Reid, RD, Quinlan, B, Riley, DL, & Pipe, AL. (2007). Smoking cessation: Lessons learned from clinical trial evidence. Curr. Opin. Cardiol. 22, 280–285.CrossRefGoogle ScholarPubMed
Williams, B. (2005). Recent hypertension trials: Implications and controversies. J. Am. Coll. Cardiol. 45, 813–827.CrossRefGoogle ScholarPubMed
Ridker, PM, Danielson, E, Fonseca, FA, Genest, J, Gotto, AM Jr, Kastelein, JJ, et al. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195–2207.CrossRefGoogle ScholarPubMed
Tardif, JC, McMurray, JJ, Klug, E, Small, R, Schumi, J, Choi, J, et al. (2008). Effects of succinobucol (AGI-1067) after an acute coronary syndrome: A randomised, double-blind, placebo-controlled trial. Lancet. 371, 1761–1768.CrossRefGoogle ScholarPubMed
Barter, PJ, Caulfield, M, Eriksson, M, Grundy, SM, Kastelein, JJ, Komajda, M, et al. (2007). Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109–2122.CrossRefGoogle ScholarPubMed
Wu, Z, Wagner, MA, Zheng, L, Parks, JS, Shy, JM 3rd, Smith, JD, et al. (2007). The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction. Nat. Struct. Mol. Biol. 14, 861–868.CrossRefGoogle ScholarPubMed
Steeg, WA, Holme, I, Boekholdt, SM, Larsen, ML, Lindahl, C, Stroes, ES, et al. (2008). High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: Significance for cardiovascular risk: The IDEAL and EPIC-Norfolk Studies. J. Am. Coll. Cardiol. 51, 634–642.CrossRefGoogle ScholarPubMed
Cohen, JC, Boerwinkle, E, Mosley, TH Jr, & Hobbs, HH. (2006). Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264–1272.CrossRefGoogle ScholarPubMed
Ballantyne, CM, Raichlen, JS, Nicholls, SJ, Erbel, R, Tardif, JC, Brener, SJ, et al. (2008). Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: A study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 117, 2458–2466.CrossRefGoogle ScholarPubMed
Glomset, JA. (1968). The plasma lecithin: cholesterol acyltransferase reaction. J. Lipid Res. 9, 155–167.Google ScholarPubMed
Cuchel, M, & Rader, DJ. (2006). Macrophage reverse cholesterol transport: Key to the regression of atherosclerosis? Circulation. 113, 2548–2555.CrossRefGoogle ScholarPubMed
Altschul, R, Hoffer, A, & Stephen, JD. (1955). Influence of nicotinic acid on serum cholesterol in man. Arch. Biochem. 54, 558–559.CrossRefGoogle ScholarPubMed
Barnhart, JW, Sefranka, JA, & McIntosh, DD. (1970). Hypocholesterolemic effect of 4,4′-(isopropylidenedithio)-bis(2,6-di-t-butylphenol) (probucol). Am. J. Clin. Nutr. 23, 1229–1233.CrossRefGoogle ScholarPubMed
Konttinen, A, & Paloheimo, J. (1963). The effects of atromid on serum lipids, proteins and some liver function tests in hypercholesterolaemic patients. J. Atheroscler. Res. 3, 525–532.CrossRefGoogle ScholarPubMed
Blacket, RB, Woodhill, J, & Brown, WD. (1964). The effect of cholestyramine (“MK 135”) on the serum cholesterol level in man. Med. J. Aust. 2, 15–19.Google ScholarPubMed
,Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (2001). Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285, 2486–2497.CrossRefGoogle Scholar
,National Academy of Sciences. Institute of Medicine. Food and Nutrition Board. (1998). Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington, DC: The National Academies Press.Google Scholar
Tunaru, S, Kero, J, Schaub, A, Wufka, C, Blaukat, A, Pfeffer, K, et al. (2003). PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med. 9, 352–355.CrossRefGoogle ScholarPubMed
Taggart, AK, Kero, J, Gan, X, Cai, TQ, Cheng, K, Ippolito, M, et al. (2005). (D)-beta-hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J. Biol. Chem. 280, 26649–26652.CrossRefGoogle ScholarPubMed
Cheng, K, Wu, TJ, Wu, KK, Sturino, C, Metters, K, Gottesdiener, K, et al. (2006). Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc. Natl. Acad. Sci. U. S. A. 103, 6682–6687.CrossRefGoogle ScholarPubMed
Guyton, JR, Goldberg, AC, Kreisberg, RA, Sprecher, DL, Superko, HR, & O'Connor, CM. (1998). Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am. J. Cardiol. 82, 737–743.CrossRefGoogle ScholarPubMed
Ballantyne, CM, Davidson, MH, McKenney, J, Keller, LH, Bajorunas, DR, & Karas, RH. (2008). Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs. simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I Study). Am. J. Cardiol. 101, 1428–1436.CrossRefGoogle ScholarPubMed
Paolini, JF, Mitchel, YB, Reyes, R, Kher, U, Lai, E, Watson, DJ, et al. (2008). Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am. J. Cardiol. 101, 625–630.CrossRefGoogle ScholarPubMed
Schoonjans, K, Staels, B, & Auwerx, J. (1996). Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37, 907–925.Google ScholarPubMed
Robins, SJ, Collins, D, Wittes, JT, Papademetriou, V, Deedwania, PC, Schaefer, EJ, et al. (2001). Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: A randomized controlled trial. JAMA. 285, 1585–1591.Google Scholar
Harris, WS, Miller, M, Tighe, AP, Davidson, MH, & Schaefer, EJ. (2008). Omega-3 fatty acids and coronary heart disease risk: Clinical and mechanistic perspectives. Atherosclerosis. 197, 12–24.CrossRefGoogle ScholarPubMed
Maki, KC, McKenney, JM, Reeves, MS, Lubin, BC, & Dicklin, MR. (2008). Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am. J. Cardiol. 102, 429–433.CrossRefGoogle ScholarPubMed
Bilheimer, DW, Goldstein, JL, Grundy, SM, & Brown, MS. (1975). Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia. J. Clin. Invest. 56, 1420–1430.CrossRefGoogle Scholar
Endo, A, Kuroda, M, & Tanzawa, K. (1976). Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS. Lett. 72, 323–326.CrossRefGoogle ScholarPubMed
Mabuchi, H, Haba, T, Tatami, R, Miyamoto, S, Sakai, Y, Wakasugi, T, et al. (1981). Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N. Engl. J. Med. 305, 478–482.CrossRefGoogle ScholarPubMed
Gerson, RJ, Allen, HL, Lankas, GR, MacDonald, JS, Alberts, AW, & Bokelman, DL. (1991). The toxicity of a fluorinated-biphenyl HMG-CoA reductase inhibitor in beagle dogs. Fundam. Appl. Toxicol. 16, 320–329.CrossRefGoogle ScholarPubMed
SoRelle, R. (2001). Baycol withdrawn from market. Circulation. 104, E9015–E9016CrossRefGoogle ScholarPubMed
Altmann, SW, Davis, HR Jr, Zhu, LJ, Yao, X, Hoos, LM, Tetzloff, G, et al. (2004). Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 303, 1201–1204.CrossRefGoogle ScholarPubMed
Sudhop, T, Lütjohann, D, Kodal, A, Igel, M, Tribble, DL, Shah, S, et al. (2002). Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 106, 1943–1948.CrossRefGoogle ScholarPubMed
Kastelein, JJ, Akdim, F, Stroes, ES, Zwinderman, AH, Bots, ML, Stalenhoef, AF, et al. (2008). Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358, 1431–1443.CrossRefGoogle ScholarPubMed
Taylor, AJ, Villines, TC, Stanek, EJ, Devine, PJ, Griffen, L, Miller, M, et al. (2009). Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med. 361, 2113–2122.CrossRefGoogle ScholarPubMed
Balmer, J, & Zilversmit, DB. (1974). Effects of dietary roughage on cholesterol absorption, cholesterol turnover and steroid excretion in the rat. J. Nutr. 104, 1319–1328.CrossRefGoogle ScholarPubMed
,U.S. Food and Drug Administration, Department of Health and Human Services. (2000). Food labeling: Health claims; plant sterol/stanol esters and coronary heart disease. Interim final rule. Fed. Regist. 65, 54686–54739.Google Scholar
Hansson, P, Valdemarsson, S, & Nilsson-Ehle, P. (1983). Experimental hyperthyroidism in man: Effects on plasma lipoproteins, lipoprotein lipase and hepatic lipase. Horm. Metab. Res. 15, 449–452.CrossRefGoogle ScholarPubMed
Packard, CJ, Shepherd, J, Lindsay, GM, Gaw, A, & Taskinen, MR. (1993). Thyroid replacement therapy and its influence on postheparin plasma lipases and apolipoprotein-B metabolism in hypothyroidism. J. Clin. Endocrinol. Metab. 76, 1209–1216.Google ScholarPubMed
Grover, GJ, Mellstrom, K, & Malm, J. (2005). Development of the thyroid hormone receptor beta-subtype agonist KB-141: A strategy for body weight reduction and lipid lowering with minimal cardiac side effects. Cardiovasc. Drug Rev. 23, 133–148.CrossRefGoogle ScholarPubMed
Erion, MD, Cable, EE, Ito, BR, Jiang, H, Fujitaki, JM, Finn, PD, et al. (2007). Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc. Natl. Acad. Sci. U. S. A. 104, 15490–15495.CrossRefGoogle ScholarPubMed
Tsimikas, S, Tsironis, LD, & Tselepis, AD. (2007). New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 27, 2094–2099.CrossRefGoogle ScholarPubMed
Schissel, SL, Jiang, X, Tweedie-Hardman, J, Jeong, T, Camejo, EH, Najib, J, et al. (1998). Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. J. Biol. Chem. 273, 2738–2746.CrossRefGoogle ScholarPubMed
Hurt-Camejo, E, & Camejo, G. (1997). Potential involvement of type II phospholipase A2 in atherosclerosis. Atherosclerosis. 132, 1–8.CrossRefGoogle ScholarPubMed
Wetterau, JR, Aggerbeck, LP, Bouma, ME, Eisenberg, C, Munck, A, Hermier, M, et al. (1992). Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science. 258, 999–1001.CrossRefGoogle ScholarPubMed
Cuchel, M, Bloedon, LT, Szapary, PO, Kolansky, DM, Wolfe, ML, Sarkis, A, et al. (2007). Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med. 356, 148–156.CrossRefGoogle ScholarPubMed
Samaha, FF, McKenney, J, Bloedon, LT, Sasiela, WJ, & Rader, DJ. (2008). Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med. 5, 497–505.CrossRefGoogle ScholarPubMed
Wren, JA, Gossellin, J, & Sunderland, SJ. (2007). Dirlotapide: A review of its properties and role in the management of obesity in dogs. J. Vet. Pharmacol. Ther. 30(Suppl 1), 11–16.CrossRefGoogle ScholarPubMed
Stein, CA, & Cohen, JS. (1988). Oligodeoxynucleotides as inhibitors of gene expression: A review. Cancer Res. 48, 2659–2668.Google ScholarPubMed
Kastelein, JJ, Wedel, MK, Baker, BF, Su, J, Bradley, JD, Yu, RZ, et al. (2006). Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation. 114, 1729–1735.CrossRefGoogle ScholarPubMed
Visser, ME, Akdim, F, Tribble, DL, Nederveen, AJ, Kwoh, TJ, Kastelein, JJ, et al. (2010). Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J. Lipid Res. 51, 1057–62.CrossRefGoogle ScholarPubMed
Okamoto, H, Yonemori, F, Wakitani, K, Minowa, T, Maeda, K, & Shinkai, H. (2000). A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 406, 203–207.CrossRefGoogle ScholarPubMed
Brown, BG, & Zhao, XQ. (2008). Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am. J. Cardiol. 101, 58B–62B.CrossRefGoogle ScholarPubMed
Barter, PJ, & Rye, KA. (2008). Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler. Thromb. Vasc. Biol. 28, 39–46.CrossRefGoogle Scholar
Reinhard, EJ, Wang, JL, Durley, RC, Fobian, YM, Grapperhaus, ML, Hickory, BS, et al. (2003). Discovery of a simple picomolar inhibitor of cholesteryl ester transfer protein. J. Med. Chem. 46, 2152–2168.CrossRefGoogle ScholarPubMed
Kuivenhoven, JA, de Grooth, GJ, Kawamura, H, Klerkx, AH, Wilhelm, F, Trip, MD, et al. (2005). Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am. J. Cardiol. 95, 1085–1088.CrossRefGoogle ScholarPubMed
Clark, RW, Sutfin, TA, Ruggeri, RB, Willauer, AT, Sugarman, ED, Magnus-Aryitey, G, et al. (2004). Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. 24, 490–497.CrossRefGoogle ScholarPubMed
Davidson, MH, McKenney, JM, Shear, CL, & Revkin, JH. (2006). Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J. Am. Coll. Cardiol. 48, 1774–1781.CrossRefGoogle ScholarPubMed
Krishna, R, Anderson, MS, Bergman, AJ, Jin, B, Fallon, M, Cote, J, et al. (2007). Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: Two double-blind, randomised placebo-controlled phase I studies. Lancet. 370, 1907–1914.CrossRefGoogle ScholarPubMed
Nissen, SE, Nicholls, SJ, Wolski, K, Howey, DC, McErlean, E, Wang, MD, et al. (2007). Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: Two randomized controlled trials. JAMA. 297, 1362–1373.CrossRefGoogle ScholarPubMed
Millar, JS, Duffy, D, Gadi, R, Bloedon, LT, Dunbar, RL, Wolfe, ML, et al. (2009). Treatment with a potent and selective PPAR-α agonist, LY518674, significantly increases apoA-I and apoA-II production rates in patients with metabolic syndrome despite no change in HDL. Arterioscler. Thromb. Vasc. Biol. 29, 140–146.CrossRefGoogle Scholar
Nissen, SE, Tsunoda, T, Tuzcu, EM, Schoenhagen, P, Cooper, CJ, Yasin, M, et al. (2003). Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA. 290, 2292–2300.CrossRefGoogle ScholarPubMed
Hunter, AK, Suda, EJ, Herberg, JT, Thomas, KE, Shell, RE, Gustafson, ME, et al. (2008). Separation of recombinant apolipoprotein A-I(Milano) modified forms and aggregates in an industrial ion-exchange chromatography unit operation. J. Chromatogr. A. 1204, 42–47.CrossRefGoogle Scholar
Tardif, JC, Grégoire, J, L'Allier, PL, Ibrahim, R, Lespérance, J, Heinonen, TM, et al. (2007). Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: A randomized controlled trial. JAMA. 297, 1675–1682.CrossRefGoogle ScholarPubMed
Tardif, JC, Heinonen, T, Orloff, D, & Libby, P. (2006). Vascular biomarkers and surrogates in cardiovascular disease. Circulation. 113, 2936–2942.CrossRefGoogle ScholarPubMed
Marcovina, SM, Crea, F, Davignon, J, Kaski, JC, Koenig, W, Landmesser, U, et al. (2007). Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: A road to integration of complementary diagnostic tools. J. Intern. Med. 261, 214–234.CrossRefGoogle ScholarPubMed
Sanz, J, & Fayad, ZA. (2008). Imaging of atherosclerotic cardiovascular disease. Nature. 451, 953–957.CrossRefGoogle ScholarPubMed
Lorenz, MW, Markus, HS, Bots, ML, Rosvall, M, & Sitzer, M. (2007). Prediction of clinical cardiovascular events with carotid intima-media thickness: A systematic review and meta-analysis. Circulation. 115, 459–467.CrossRefGoogle ScholarPubMed
Patel, S, & Celermajer, DS. (2006). Assessment of vascular disease using arterial flow mediated dilatation. Pharmacol. Rep. 58(Suppl), 3–7.Google Scholar
Franco, AC, & Nissen, SE. (2001). Coronary intravascular ultrasound: Implications for understanding the development and potential regression of atherosclerosis. Am. J. Cardiol. 88, 7M–20M.CrossRefGoogle ScholarPubMed
Aziz, K, Berger, K, Claycombe, K, Huang, R, Patel, R, & Abela, GS. (2008). Noninvasive detection and localization of vulnerable plaque and arterial thrombosis with computed tomography angiography/positron emission tomography. Circulation. 117, 2061–2070.CrossRefGoogle ScholarPubMed
Nissen, SE, Tardif, JC, Nicholls, SJ, Revkin, JH, Shear, CL, Duggan, WT, et al. (2007). Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356, 1304–1316.CrossRefGoogle ScholarPubMed
Kastelein, JJ, Leuven, SI, Burgess, L, Evans, GW, Kuivenhoven, JA, Barter, PJ, et al. (2007). Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 356, 1620–1630.CrossRefGoogle ScholarPubMed
Brousseau, ME, Schaefer, EJ, Wolfe, ML, Bloedon, LT, Digenio, AG, Clark, RW, et al. (2004). Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350, 1505–1515.CrossRefGoogle ScholarPubMed
Morehouse, , Sugarman, ED, Bourassa, PA, Sand, TM, Zimetti, F, Gao, F, et al. (2007). Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J. Lipid Res. 48, 1263–1272.CrossRefGoogle ScholarPubMed
Forrest, MJ, Bloomfield, D, Briscoe, RJ, Brown, PN, Cumiskey, AM, Ehrhart, J, et al. (2008). Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br. J. Pharmacol. 154, 1465–1473.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×